Oncolytic adenoviruses are a promising treatment alternative for many advanced cancers, including colorectal cancer. However, clinical trials have demonstrated that single-agent therapy in advanced tumor masses is rarely curative. Poor spreading of the virus through tumor tissue is one of the major issues limiting efficacy. As oncolytic viruses kill preferentially cancer cells, high extracellular matrix (ECM) content constitutes potential barriers for viral penetration within tumors. In this study, the ECM-degrading proteases relaxin, hyaluronidase, elastase and macrophage metalloelastase (MME) were tested for their antitumor efficacy alone and in combination with oncolytic adenovirus. MME improved the overall antitumor efficacy of oncolytic adenovirus in subcutaneous HCT116 xenografts. In a liver metastatic colorectal cancer model, intra-tumoral treatment of primary tumors from HT29 cells with MME monotherapy or with oncolytic adenovirus inhibited tumor growth. Combination therapy showed no increased mortality in comparison with either monotherapy alone. Contradictory results of effects of MME on tumorigenesis and metastasis formation have been reported in the literature. This study demonstrates for the first time in a metastatic animal model that MME, as a monotherapy or in combination with oncolytic virus, does not increase tumor invasiveness. Co-administration of MME and oncolytic adenovirus may be a suitable approach for further optimization aiming at clinical applications for metastatic colorectal cancer.
Introduction
Colorectal cancer is the fourth most common type of cancer in men and the third most common in women worldwide, with over one million new patients diagnosed each year. Incidence rates have increased during past decades, whereas 5-year survival rates have improved but remain between 60 and 40% in different countries. 1, 2 Metastatic colorectal cancer, being the most aggressive form of the disease, can be cured only rarely. Even though early detection and prevention strategies have a key role in improving colorectal cancer statistics, also new therapeutic options are needed. Numerous preclinical studies have shown efficacy of oncolytic adenoviruses for treatment of several tumor types, 3 including colorectal cancer. 4 However, clinical application of early-generation agents has resulted in limited efficacy. 5 Nevertheless, when used in combination with other agents, even early trials with rather attenuated viruses seem to suggest the potential for efficacy, supporting the feasibility of developing the approach further. 6 A key finding has been that several factors related to the poor spreading of the virus through tumor tissue limit the efficacy of oncolytic virus therapy. 7 Given its morphological characteristics, tumor tissue can compromise the access of different drugs to all areas of a tumor. In normal tissue, interstitial pressure is slightly lower than intra-capillary pressure, creating a transcapillary gradient between these compartments. This outward transcapillary flow permits tissue homeostasis (that is, tissue nutrition and oxygenation) and, also, facilitates drug availability. By contrast, hydrostatic and osmotic pressure are often elevated in solid tumors, which results in increased interstitial fluid pressure creating a barrier for drug delivery. [8] [9] [10] This is particularly true for colorectal carcinoma. 11 The reasons for increased interstitial fluid pressure are not fully understood but are thought to involve increased blood vessel permeability and leakiness due to tumor-associated growth factors, lymph vessel abnormalities, interstitial fibrosis, abnormal contraction of the interstitial space by stromal fibroblasts and overexpression of tumor-related extracellular matrix (ECM) components. 12 ECM, as a physical barrier, may also directly limit the spreading of the therapeutics. 13 Macrophage metalloelastase (MME, also known as MMP-12) belongs to a family of zinc-dependent endoproteases and it has proteolytic activity on most of the components of the tumor tissue-derived ECM (elastane, fibronectin, laminin, collagen-I and IV, fibrinogen, and plasminogen).
14 MME is also required for different processes related to ECM re-modulation and invasion both in normal 15 and malignant tissues. 16 Contradictory results of effects of MME on tumorigenesis and metastasis formation have been reported. MME converts plasminogen into angiostatin, an important inhibitor of tumor angiogenesis, 17 and these antiangiogenic properties of MME have been shown to result in tumor growth inhibition in syngeneic mouse models. 18, 19 In clinical squamous cell carcinoma specimens, high MME expression correlates with increased invasiveness and aggressive histology, 20 but overexpression of MME has also been associated with survival benefit and a lower microvessel density in colorectal cancer patients. 21 Therefore, theoretically MME has both pro-and antitumor effects, which may limit its use as a therapeutic agent by itself.
In this study, we propose MME as a potential coadjuvant for oncolytic adenovirus to increase viral spreading by degrading stromal barriers that impede access of adenovirus to tumor cells. To evaluate the role of MME in colorectal cancer progression, we assessed the effect of MME on tumor growth and metastasis formation by using a murine metastatic colorectal cancer model. 22 We also tested the efficacy of MME as a co-adjuvant together with intratumorally administered oncolytic adenovirus in two different colorectal cancer animal models.
Materials and methods

Cell lines
The human colorectal cancer cell lines HCT116 and HT29 were acquired from ATCC (American Type Culture Collection), cultured in the recommended growth media with 10% fetal bovine serum and maintained in a humidified atmosphere at 37 1C and 5% CO 2 .
Proteases
Elastase and hyaluronidase (both from Sigma-Aldrich, Helsinki, Finland) were dissolved in saline (0.9% NaCl) aqueous solution and high-concentration stocks were stored at À80 1C. Relaxin was provided by Dennis R Stewart of Corthera (San Mateo, CA, USA) in 1.02 mg ml À1 aqueous solution. Phosphate-buffered saline (PBS) was used as a diluent to prepare equimolar dilutions of proteases prior to use. Preparation of human MME has been described earlier. 23 Proteolytic activity of MME after expression, refolding and purification was determined by a chromogenic assay using resorufin-casein (Universal Protease Substrate, cat. no. 11 080 733 001; Roche Diagnostics, Espoo, Finland). The protein was diluted 1:10 with activity buffer (10 mM Tris, 200 mM NaCl, 2.5 mM CaCl 2 (pH 8.0)) containing 0.2% w/v of resorufin-casein. The test mixture was incubated for 30 min at 37 1C. The reaction was stopped by adding 5 volumes of 5% trichloroacetic acid. After an incubation period of 10 min at 37 1C the precipitated casein was pelleted by centrifugation (10 min at 14 000 g at room temperature). A 400-ml volume of the supernatant was added to 600 ml of test buffer (500 mM Tris/HCl (pH 8.8)) in a plastic cuvette and mixed. The intensity of the pink color (cleaved-off resorufin) was measured against a blank cuvette containing the same test mixture but no protein, using a Perkin Elmer Spectrophotometer (l ¼ 12) at 574-nm wavelength.
Viruses
Non-replicating Ad5lucRGD and oncolytic (replicationcompetent in tumor cells) Ad5-D24-RGD adenoviruses have been described previously. 24, 25 Ad5lucRGD and Ad5-D24-RGD were propagated in 293 and A549 cells, respectively, and purified in cesium chloride gradients. The particle concentrations for Ad5lucRGD and Ad5-D24-RGD were measured at 260 nm, being 4.9 Â 10 11 and 1.1 Â 10 12 viral particles (VPs) per ml, respectively, and standard TCID50 tests in 293 cells were performed to determine functional units, and were assessed to be 9.3 Â 10 9 and 2.8 Â 10 10 PFUs per ml, respectively. Viral oncolytic potency in human colorectal cancer cells Cells were infected with 4500 VPs per cell of the replication-competent virus Ad5-D24-RGD in DMEM media containing 2% fetal calf serum. After 2 h, the growth medium was replaced with DMEM containing 5% fetal calf serum. After a 12-h incubation, 2.6 Â 10eÀ10 mols of each protease were added to 5% DMEM. Cell viability was analyzed after 1, 2, 4 and 7 days using the mitochondrial activity-based 3-
Analysis of transgene expression
assay (Cell Titer 96 AQueous One Solution Cell Proliferation Assay; Promega, Stockholm, Sweden).
Animals
All animal experiments were conducted according to the rules set by the Provincial Government of Southern Finland (Permit number ESLH-2008-01986/Ym-23).
Pathogen-free, 3-to 4-week-old female NMRI nude mice and pathogen-free, 10-to 11-week-old female SCID (severe combined immunodeficient) mice were purchased from Taconic (Ejby, Denmark) and quarantined for 2 weeks. The animals were fed ad libitum and maintained in HEPA-filtered cages. The SCID mice were used for experiments at the age of 125 days or older when the spleens were fully developed. This has earlier been shown to be crucial for proper implantation of the cancer cells.
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Magnetic resonance imaging Magnetic resonance imaging (MRI) studies were performed with a 4.7-T scanner (PharmaScan; Bruker BioSpin, Ettlingen, Germany) using a 90-mm shielded gradient capable of producing a maximum gradient amplitude of 300 mT/m with an 80-ms rise time. A linear birdcage RF coil with an inner diameter of 38 mm was used. T2-weighted images were acquired by rapid acquisition using a relaxation enhancement (RARE) sequence (TR/TE eff ¼ 3767/36 ms, matrix size ¼ 256 Â 256, Rare Factor ¼ 8, field-of-view ¼ 33 Â 33 mm 2 , 32 slices, slice thickness ¼ 0.7 mm, number of averages ¼ 8).
Effect of proteases on the oncolytic potency of Ad5-D24-RGD in a subcutaneous murine model Subcutaneous HCT116 tumors were induced in both flanks of NMRI nude mice by injection of 1 Â 10e7 cells in a 100-ml volume of DMEM without supplements. Tumors were allowed to grow for 14 days. Thereafter, 1 Â 10eÀ9 mols of each protease in an injection volume of 25 ml using PBS as vehicle were injected intratumorally. Control animals received PBS only. The number of animals in each group was 4. Twenty-four hours later half of the animals from each protease group received 1.0 Â 10e7 PFUs of Ad5-D24-RGD intratumorally in a 50-ml volume of 0% DMEM. Tumor volumes were calculated according to the formula V ¼ 1/2nlengthn width 2 (refs. 26, 27 ) after 5 days and data were expressed as relative volumes normalized to their volume 1 day before adenoviral treatment.
Metastatic spleen-to-liver colorectal cancer model The surgical procedure was similar to that described previously. 28 Briefly, 125-day-old female SCID mice were anesthetized with a ketamine (Ketaminol 75 mg kg À1 ; Intervet, Boxmeer, the Netherlands)/dexmedetomidine (Dexdormitor 1 mg kg À1 ; Orion Pharm., Espoo, Finland) admixture and the spleen was exteriorized through a left lateral flank incision. Tumors were established by intrasplenic injection of 1 Â 10e6 HT29 cells as described earlier.
Ad5-D24-RGD and/or MME were administered 21 days after tumor cell implantation by intra-tumoral injection to splenic primary tumors. Solutions containing 2.3 Â 10eÀ10 mols of MME in 2-ml volume and an adenoviral suspension containing 1.1 Â 10e7 VPs in 8-ml volume were prepared extemporally and a single microinjection of 10-ml volume was administered to each animal. Mock animals received PBS only. Tumor growth (both in the spleen and liver) was followed weekly with MRI for 4 weeks. Tumor volumes were estimated by using the formula V ¼ Area Â Slice thickness. For intra-hepatic tumors, the total area occupied by tumors in each slice was included in the formula. The number of animals in each group was 12 (mock), 10 (Ad5-D24-RGD), 8 (MME) and 12 (Ad5-D24-RGD þ MME).
Statistical analyses
All analyses were performed using PASW Statistics 17 for Windows. One-way analysis of variance followed by Dunnett's Pairwise Multiple Comparison t-test was used for all analyses. A value for Po0.05 was considered statistically significant.
Results
Analysis of transgene expression HCT116 and HT29, two human colorectal cancer cell lines, were infected with Ad5lucRGD alone or in a mixture of equimolar doses of elastase, hyaluronidase, relaxin or MME and the virus (Figure 1 ). Given that cell monolayers do not develop any ECM, we aimed to study whether proteases would have any direct effect on cancer cells that would alter the transfection efficiency of adenovirus vector. In general, proteases had no clear effect on the transduction efficiency of Ad5lucRGD. In HCT116 cells (Figure 1a) , hyaluronidase slightly decreased transgene expression at the lowest viral dose, whereas other doses resulted in no difference in comparison with Ad5lucRGD treatment alone. Relaxin slightly decreased transgene expression in combination with a viral dose of 1000 VPs per cell, whereas elastase and MME increased transgene expression at viral doses of 200 and 1000 VPs per cell. In HT29 cells (Figure 1b) all proteases slightly increased transgene expression. This was seen with all viral doses except with the lowest dose in combination with relaxin and hyaluronidase.
Effect of protease on cell viability and viral oncolytic potency in vitro The effect of proteases on the viability of human colorectal cancer cell lines was assessed in HCT116 and HT29 cells by using MTS assay (Figure 2a ). For both cell lines, MME reduced the viability of cancer cells at all time points. By contrast, hyaluronidase, relaxin and elastase either slightly increased or had no effect on cell viability. The only exception for this was hyaluronidase, which slightly decreased the viability of HT29 cells after 7 days of incubation.
The effect of proteases on cell viability in combination with oncolytic adenovirus Ad5-D24-RGD was assessed similarly. However, none of the proteases showed difference in cell killing in comparison with virus treatment alone in this in vitro assay, which does not take into account the effect of ECM on intra-tumoral viral penetration (Figure 2b ).
Effect of protease on adenoviral oncolytic potency in a subcutaneous murine model Subcutaneous HCT116 tumors were induced in NMRI nude mice (4 mice per group; 2 tumors per animal) and treated intratumorally with relaxin, hyaluronidase, elastase or MME. Twenty-four hours later, half of the animals were treated intratumorally with oncolytic adenovirus Ad5-D24-RGD. Control animals (four animals per group) received PBS intratumorally on two consecutive days, or PBS followed by intra-tumoral injection of oncolytic virus. Tumor volumes were measured after 5 days and normalized to their volume 1 day before treatment with oncolytic adenovirus (Figure 3) . Oncolytic virus treatment alone did not reduce tumor growth significantly. More pronounced inhibition in tumor growth was seen with the combination treatment of oncolytic virus and each protease, but no statistically significant differences between oncolytic virus therapy alone and combination therapies were seen. However, statistically a significant reduction in tumor growth in comparison with untreated animals was seen if oncolytic virus was combined with relaxin, elastase or MME (Po0.05; mock versus each combination treatment), but none of these proteases reduced tumor growth significantly alone. In contrast to this, intra-tumoral treatment with hyaluronidase showed significant inhibition in tumor growth alone (Po0.01). Animals did not show signs of post-treatment distress in any treatment groups.
Effect of MME on oncolytic efficacy of adenovirus in splenic primary tumors and liver metastases The human cancer cell line HT29 was used to establish intra-splenic tumors in SCID mice. MME alone showed an inhibitory effect on tumor cell growth in vitro (Figure 2a ) and was therefore used in this spleen-to-liver animal model. Twenty-one days after cell implantation all intra-splenic tumors were at least of 2-mm diameter in size (at least 1 week before liver metastases appeared); animals (8-12 animals per group) were injected intratumorally with oncolytic adenovirus alone, MME alone or a combination of oncolytic virus and MME. Tumor volumes in the spleen and liver, and the number of liver metastases were followed weekly by MRI.
Untreated and MME-treated splenic tumors grew steadily until the end of experiment, whereas equal reduction in tumor growth was seen with oncolytic adenovirus alone and in combination with MME ( Figure 4a ). Both treatments showed statistically significant difference in comparison wit untreated tumors 3 weeks from treatments and thereafter.
In general, liver tumors could be first detected by MRI 4 weeks after injection of cancer cells into the spleen (Figure 4b ). All mock-treated (PBS) animals (n ¼ 12) showed development of liver tumors by day 14 after intratumoral treatment of primary tumors in the spleen. A total of 88 (7/8), 70 (7/10) and 92% (11/12) of animals receiving intra-tumoral injection of MME alone, oncolytic virus alone and combination treatment into their primary tumors developed liver tumors, respectively. All treatments seemed to decrease the growth of liver tumors Figure 1 Proteases do not compromise adenoviral transduction of cancer cells in vitro. Two human colorectal cancer cell lines HCT116 (a) and HT29 (b) were infected with Ad5lucRGD (Ad) at doses of 200, 1000 or 5000 VPs per cell with or without 2.6 Â 10eÀ10 mols of relaxin, hyaluronidase, elastase or MME. Luciferase expression (relative light units, RLU) was measured 24 h later. Data are presented as the mean of three replicates ± s.d. after normalization for protein concentration. *Po0.05, combination treatment versus corresponding adenovirus only. MME, macrophage metalloelastase; VP, viral particle.
Antitumor efficacy of MME and MME þ oncolytic adenovirus S Lavilla-Alonso et al equally in comparison with untreated mock animals, resulting in smaller tumor size (Figure 4b ). However, in comparison with untreated animals, statistical significance was achieved in groups treated with oncolytic virus alone and protease alone (P ¼ 0.042 in both). The difference between untreated and combination-treated animals was not significant (P ¼ 0.09) apparently owing to slightly bigger variation in the size of liver tumors in the combination treatment group. No statistically significant differences in the numbers of liver tumors were seen between groups (Figure 4c ). Animals did not show signs of post-treatment distress in any treatment groups. Representative MRI images of spleen and liver tumors from untreated and combination-treated animals are presented in Figure 5 . Discussion MME, relaxin, hyaluronidase and elastase have earlier been shown to re-modulate ECM and/or have proteolytic activity on most tumor-derived ECM proteins. [29] [30] [31] [32] [33] In our study, MME was the only protease, which clearly decreased the viability of HCT116 and HT29 colorectal cancer cells in vitro. MME also slightly enhanced the cellkilling potency of oncolytic adenovirus in both cell lines, Figure 2 Proteases have no effect on the oncolytic potency of Ad5-D24-RGD in vitro. (a) Non-infected HCT116 and HT29 human colorectal cancer cells were incubated with proteases. (b) Cells were infected with oncolytic adenovirus Ad5-D24-RGD (OV) at a dose of 4500 VPs per cell. Twelve hours after infection, 2.6 Â 10eÀ10 mols of relaxin, hyaluronidase, elastase or MME was added to the cells. Cell viability was analyzed 1, 2, 4 and 7 days later using the mitochondrial activity-based MTS assay. Data are presented as the mean of three replicates ± s.d. *Po0.05; ***Po0.001, protease versus mock. MME, macrophage metalloelastase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; VP, viral particle. Figure 3 Proteases increase the antitumor effect of Ad5-D24-RGD in a subcutaneous murine model. Human colorectal cancer xenografts (HCT116) in NMRI nude mice were treated intratumorally with 1.0 Â 10eÀ9 mols of relaxin, hyaluronidase (Hyal), elastase or MME. Twenty-four hours later, oncolytic adenovirus Ad5-D24-RGD (OV) at a dose of 1.0 Â 10e7 VPs was administered intratumorally. Tumor volumes were analyzed 5 days later. Data are presented as the mean of 4 to 8 measurements ± s.d. and normalized to tumor volume 1 day before treatment with oncolytic adenovirus *Po0.05, treatment versus mock (white bar). MME, macrophage metalloelastase; VP, viral particle.
Antitumor efficacy of MME and MME þ oncolytic adenovirus S Lavilla-Alonso et al although increases were not significant if compared with adenovirus treatment alone. Two-dimensional cell culture systems may not be able to fully capture the relevance of ECM and therefore increased efficacy was not expected.
In an optimal combination of protease and oncolytic virus, the protein capsids of viral particles should not be injured by proteases. To assess this, we performed an in vitro transductional assay and demonstrated that proteases did not hamper the entry of adenovirus as no reduction in adenoviral transduction levels was seen after protease/virus co-treatment. On the contrary, all tested proteases slightly increased transduction. In line with this, earlier studies have shown that a relaxin-expressing adenovirus increases the transduction of cancer cells in a three-dimensional in vitro spheroid assay. 34 In this work, we demonstrate that the ECM-degrading proteases relaxin, elastase and MME enhance the antitumor efficacy of oncolytic adenovirus in vivo in subcutaneous colorectal cancer xenografts. This corresponds with the earlier studies by Kim et al. 34 and Ganesh et al.,
29 who used relaxin-expressing oncolytic Figure 4 MME and oncolytic adenovirus Ad5-D24-RGD decrease the growth of primary tumors and liver metastases. Human colorectal cancer cells (HT29) were injected into the spleen of SCID mice. Twenty-one days later, before liver tumors could be detected by MRI, primary tumors in the spleen were injected with an admixture of 1.1 Â 10e7 VPs of Ad5-D24-RGD and 2.3 Â 10eÀ10 mols of MME (12 mice). Control animals received OV alone (10 mice), MME alone (8 mice) or PBS only (12 mice). Spleen tumor (a) and liver tumor (b) volumes, and the number of liver tumors (c) were followed weekly by MRI. Data are presented as the mean±s.d. *Po0.05; **Po0.01; ***Po0.001, treatment versus mock. MME, macrophage metalloelastase; MRI, magnetic resonance imaging; SCID, severe combined immunodeficient; VP, viral particle. Figure 5 Antitumor activity of MME with Ad5-D24n-RGD. Primary tumors in the spleens of MME and oncolytic virus treated animals were smaller in comparison with untreated (mock) primary tumors. Treatment of primary tumors with MME and oncolytic virus resulted in smaller liver metastases in comparison with untreated mice. MME, macrophage metalloelastase.
Antitumor efficacy of MME and MME þ oncolytic adenovirus S Lavilla-Alonso et al adenoviruses and showed an increase in viral spread and improved oncolytic potency in comparison with viruses without relaxin. The only protease that did not show additional utility in combination with virus was hyaluronidase, which had a clear antitumor effect as a single agent. By contrast, Ganesh et al. 35 reported that combination of a chimeric adenovirus serotype-5-based oncolytic virus and an isoform of hyaluronidase increased the antitumor efficacy and survival in comparison with oncolytic virus alone. This could be due to differences in virus, hyaluronidase isoform, cell lines and animal models used.
The involvement of tumor-associated proteolytic enzymes in metastatic development has been studied in several cell culture and in vivo models. Silvertown et al. 36 showed that relaxin can increase cell invasiveness in vitro, probably by ECM (mainly collagen) degradation in canine cancer cell lines. This raises the concern of whether tumors could become more metastatic after co-administration or co-expression of ECM-degrading proteases. If proteases can be pro-metastatic, the overall outcome could be determined by the relative importance of the improved antitumor effect mediated by enhanced intratumoral dissemination versus the negative impact of increased metastases. In the case of patients who already have widely metastatic disease, improved treatment efficacy may be more important than possible effects on future metastases. Advanced tumors often cause a life-threatening situation whereas new metastases are likely to occur at later time points. Thus, the approach could be feasible for clinical use even if pro-metastatic effects cannot be excluded.
Interestingly, previous publications suggest that the positive effect of proteases can outweigh possible negative effects. For example, intra-tumoral treatment of primary tumors with replication-deficient or oncolytic adenoviruses coding for relaxin was shown to reduce metastases in lungs of mice in comparison with untreated animals. 34 Ganesh et al. 29 analyzed the amount of metastasizing cells in the lungs and lymph nodes released from the intratumorally treated subcutaneous primary tumors, and showed that mice treated with relaxin-expressing adenoviruses had less tumor cells in the metastatic organs than those treated only with adenovirus. Similarly, intratumorally administered hyaluronidase alone or in combination with oncolytic adenovirus did not increase the metastatic potential of treated tumors. 35 To our knowledge, the effect of MME on primary tumor invasiveness has not been studied in animal models before. Studies of the levels of MME in tumors from clinical explants and tumor progression have showed contradictory results. Analysis of clinical vulvar squamous cell carcinoma samples showed a correlation between high levels of MME expression in cancer cells and more aggressive/de-differentiated tumors, whereas high levels of MME expressed by tumor-infiltrating macrophages were related to less aggressive and less invasive tumors. 20 However, no direct correlation between MME expression in cancer cells or in macrophages and the rate of metastases or survival was found. 20 Nonetheless, in clinical samples of primary colorectal carcinoma, high tumor-to-normal ratios of MME levels correlated with lower depth of intestinal, lymphatic and vascular invasion, and with better survival rates. 21 Thus, tumor-specific expression of MME seems an appealing strategy for colorectal cancer.
In order to assess metastatic development after different treatment combinations of oncolytic adenovirus and MME, we used a spleen-to-liver metastatic colorectal cancer model that features intra-splenic primary tumors that spontaneously metastasize to the liver. When combined with MRI, we believe this model is highly sensitive for non-invasive assessment of tumor growth and early detection of metastases. Our results suggest that intra-tumoral administration of MME does not increase the invasiveness of HT29 colorectal cancer splenic tumors as the total volume of liver metastases was decreased in MME-treated animals as efficiently as in combination treatment with oncolytic adenovirus and MME. Oncolytic adenovirus alone also decreased the volume of liver metastases.
Interestingly, MME as a monotherapy reduced the volume of liver metastases, but did not reduce the growth rate of primary tumor itself. MME is known to convert plasminogen into angiostatin, 37 a powerful angiogenesis inhibitor. 17, 38 Furthermore, high expression on MME in clinical colorectal tumors has been associated with lower frequency of vascular, lymphatic and intestinal wall invasion. 21 Therefore, this might explain why in our model MME injection had an effect on metastases but not the primary tumor, whereas the combination with oncolytic virus had an effect on both.
Oncolytic virus with or without MME had a smaller effect on the number of liver metastases than on their size. This suggests that the anti-vascular effect of MME may be relevant, as tumors can grow to a few millimeters before they need vascular supply. 39 Demonstrating the utility of the MRI method used here, we were able to detect even such small tumors. Also, the oncolytic effect may require tumors before the virus can start to replicate, leading to inhibition of growth. Thus, metastases may be able to initiate before the oncolytic effect starts to play a role.
In this study, combination treatment with oncolytic adenovirus and MME improved treatment results in a subcutaneous mouse model of colorectal carcinoma in comparison with single treatments with either agent alone (single therapies did not significantly reduce tumor growth in comparison with untreated animals but combination therapy did). MME as monotherapy or in combination with oncolytic adenovirus did not significantly change the number of liver metastasis as assessed in the metastatic human colorectal cancer murine model. No signs of treatment-related distress were seen in animals receiving combination treatment with oncolytic adenovirus and MME. However, safety of the approach requires further studies. Combination therapy with MME and oncolytic adenovirus may be a suitable candidate for further optimization aiming at clinical applications.
